Midas Letter and C-Suite are excited to announce Midas Letter LIVE. Midas Letter highlights the stocks and stories to watch in the Canadian markets today. Host James West is a recognized authority on investing in the emerging company segment having been a regularly featured guest on Business News Network, CNBC, Bloomberg, Reuters, and CTV. James West and guests provide comprehensive fundamental & technical analysis on all trending business and investment news, while interviewing the top CEOs of all public companies and analysts with the highest reputations in the business. Midas Letter is excited to feature all investing content on C-suite.
Amyris Inc (NASDAQ:AMRS) Leading Biosynthesis Charge at Paradigm Capital Conference
Amyris Inc (NASDAQ:AMRS) (FRA:3A01) CEO John Melo explains how the company makes natural products in sustainable fashion, while speaking at the recent Paradigm Capital Biosynthesis Conference. Amyris employs a fermentation process using yeast derived from sustainable sugarcane. The company’s ingredients are used in a wide variety of products including skin care and fragrances. By developing the emollient squalene through a fermentation process, Amyris has significantly expanded the market for the vital skin care ingredient, without harming its natural source. Melo sees increased availability of existing ingredients as the most important result of metabolic engineering. He suggests that making cannabinoids through a fermentation process will make them a viable alternative to other substances and a potential solution to the opioid crisis. Melo addresses the company’s evolution from a renewable fuel company to a metabolic engineering company that is commercializing multiple products annually.